Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgkin Lymphoma
NCT07171827Completed
- Sponsor
- Helwan University
- Start
- Mar 2023
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by Helwan University. Started Mar 2023; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT07171827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171827.